Revolutionising early cancer detection and diagnosis.

In 2019 there were 17m new worldwide cancer diagnosis, by 2040 it’s predicted to rise to 27.4m new cancer cases, +62%. The four most common worldwide cancers are lung, female breast, colorectum and prostate cancer. These four account for more than 40% of all global cancers and the ones Applied Biotech is developing tests for.

We are developing and manufacturing a range of globally affordable innovative cancer tests using two different technologies; INNOPLEX and TEVIPLEX. Both of these technologies have significant resource, time and cost benefits over current cancer testing methodologies such as FISH. Our faster, accurate, digital tests enable healthcare providers to; reduce patient anxiety, apply earlier less vigorous treatments and the ability to easily monitor and modify treatment to ensure effectiveness.

INNOPLEX research only and in vitro biopsy cancer tests covering the following cancers; breast, colorectal, brain (Glioblastoma multiforme) and lung will launch in 2020-21. TEVIPLEX early cancer screening and ongoing monitoring through simple blood tests will be available from 2021.

Applied Biotech INNOPLEX HER2 Confirmatory Test (RUO) is available to order.

Please complete the Contact Form so we can keep you updated as our new cancer testing kits launching during 2020 and 2021.